We have several new scleroderma trials! Several exciting early trials using anti – TGFbeta monoclonal agents for scleroderma (diffuse skin up to 10 years in duration) as well as several phase 3 trials looking an anifrolumab (interferon antagonist) in diffuse scleroderma. We also have new trials for ILD, including an exciting molecule that hopes to affect both skin and lung. Please reach out to the contacts below if you have any questions. 

Thanks so much for always supporting clinical trials in scleroderma!